Dennis Cho's questions to Recursion Pharmaceuticals Inc (RXRX) leadership • Q2 2025
Question
Dennis from Jefferies asked about the CDK7 combination expansion cohort in ovarian cancer, specifically the standard of care being allowed and the efficacy benchmarks for ORR and PFS.
Answer
Chief R&D and Commercial Officer Najat Khan stated the standard of care will include single-agent chemo plus bevacizumab (beva). She noted the median PFS for that combination is around 6.7 months, and Recursion aims for a meaningful improvement. She also mentioned the team will assess other critical endpoints.